Immunic: Multiple Sclerosis Data In H2 2023 Could Provide Major Shift

Feb. 07, 2023 7:22 AM ETImmunic, Inc. (IMUX)


  • Interim results from the phase 2 CALLIPER study using IMU-838 for treatment of patients with Progressive MS are expected in the 2nd half of 2023; topline results are end of 2024.
  • Final results from the phase 3 ENSURE study, using IMU-838 for the treatment of patients with relapsing multiple sclerosis, are expected by the end of 2025.
  • Results from the phase 1 study using IMU-856 for the treatment of patients with Celiac Disease are expected in 2023.
  • An update from management on whether or not they will continue to advance IMU-935 for the treatment of patients with Psoriasis will be provided in Q1 of 2023.
  • This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central. Learn More »

Colorful test tubes isolated on white background 3d rendering

koya79/iStock via Getty Images

Immunic, Inc. (NASDAQ:IMUX) is a great speculative biotech play to look into, because it has already established some proof of concept in a phase 2 study using its drug vidofludimus calcium (IMU-838) in treating patients with relapsing

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis profile picture
Actionable ideas on small-large cap biotech stocks through deep analysis.

I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha.

You can follow me on under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.